Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment.

Drugs Context · 2018 · PMC6089617 · PMID 30116284

Europe PMC DOI

hedged sentence

0.0619

closest p · 1.2× alpha

0.0619

boldest claim

The sentences

not quite statistically significantp =0.0619so close (0.05 < p ≤ 0.1)

The results were not quite statistically significant at 12 and 52 weeks (−3.57 g/m 2 , p =0.0619 and −2.80 g/m 2 , p =0.0529); the authors note that sacubitril/valsartan may have a positive effect on LV mass reduction independent of BP lowering. 13 Similar findings to this study were reported by Williams et al. who evaluated the same drugs and doses over a 12-week period.

also in 341 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.